GLP-1 Market

The GLP-1 (glucagon-like peptide-1) market consists of receptor agonist therapies used in glucose metabolism. These therapies primarily target patients with type 2 diabetes, obesity, and cardiovascular risk, with healthcare providers being the main customers. Key growth drivers include the expanding application of these drugs into broader chronic disease management, continuous pharmaceutical innovation in drug delivery such as oral formulations, and rising demand in emerging markets due to an increase in lifestyle-related metabolic disorders.